Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism
- PMID: 3932988
- PMCID: PMC2418387
- DOI: 10.1136/pgmj.61.719.779
Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism
Abstract
Established partial seizures are often refractory to treatment and many patients receive polypharmacy. An attempt was made to improve seizure control with the substitution of carbamazepine (CBZ) for existing treatment in 7 consecutive unremitting cases of partial epilepsy referred by their physicians as 'intractable'. This produced a significant improvement in control of partial (P less than 0.02) and secondary generalized (P less than 0.01) seizures, with 5 patients experiencing a 50% or greater reduction in seizure frequency. A single patient suffered a generalized seizure during the period of changeover. In 3 cases auto-induction of CBZ metabolism resulted in temporary loss of seizure control which was restored by an increase in dose. A policy of planned substitution of CBZ in partial epilepsy previously regarded as intractable may be successful in selected patients. The possible deleterious effect of CBZ auto-induction should be anticipated.
Similar articles
-
[A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy ].Srp Arh Celok Lek. 2002 Jan-Feb;130(1-2):19-26. doi: 10.2298/sarh0202019v. Srp Arh Celok Lek. 2002. PMID: 12073283 Clinical Trial. Serbian.
-
Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy.Ther Drug Monit. 1994 Dec;16(6):537-40. Ther Drug Monit. 1994. PMID: 7878690 Clinical Trial.
-
New statistical method for analyzing time to first seizure: example using data comparing carbamazepine and valproate monotherapy.Epilepsia. 2007 Jun;48(6):1173-8. doi: 10.1111/j.1528-1167.2007.01036.x. Epilepsia. 2007. PMID: 17553118
-
Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten.Neurology. 1999 Oct 12;53(6):1170-4. doi: 10.1212/wnl.53.6.1170. Neurology. 1999. PMID: 10522867 Review.
-
Intravenous carbamazepine: a new formulation of a familiar drug.Expert Rev Neurother. 2017 Sep;17(9):851-860. doi: 10.1080/14737175.2017.1364993. Epub 2017 Aug 16. Expert Rev Neurother. 2017. PMID: 28783998 Review.
Cited by
-
Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients.Br J Clin Pharmacol. 1992 Jan;33(1):111-4. doi: 10.1111/j.1365-2125.1992.tb04009.x. Br J Clin Pharmacol. 1992. PMID: 1540481 Free PMC article.
-
A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.Br J Clin Pharmacol. 1989 Mar;27(3):313-22. doi: 10.1111/j.1365-2125.1989.tb05371.x. Br J Clin Pharmacol. 1989. PMID: 2655682 Free PMC article. Clinical Trial.
-
Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.Br J Clin Pharmacol. 1992 Jun;33(6):611-5. doi: 10.1111/j.1365-2125.1992.tb04089.x. Br J Clin Pharmacol. 1992. PMID: 1389933 Free PMC article.
-
Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.Br J Clin Pharmacol. 1991 Jan;31(1):65-71. doi: 10.1111/j.1365-2125.1991.tb03858.x. Br J Clin Pharmacol. 1991. PMID: 2015172 Free PMC article.
-
Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients.Eur J Clin Pharmacol. 1986;31(2):195-9. doi: 10.1007/BF00606658. Eur J Clin Pharmacol. 1986. PMID: 3803416 Clinical Trial.